galantamine has been researched along with Schizophrenia in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 17 (51.52) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Blais, CM; Choueiry, J; Fisher, D; Knott, V; Labelle, A; Shah, D; Smith, D | 1 |
| Hong, H; Hou, W; Koola, MM; Looney, SW; Pillai, A | 1 |
| Buchanan, RW; Carpenter, WT; Gold, JM; Kelly, DL; Koola, MM; McMahon, RP; Strauss, GP; Weiner, E | 1 |
| Aaronson, ST; Davis, W; Koola, MM; Kozak, R; Meissen, JK; Nikiforuk, A; Sawant-Basak, A; Sklar, J | 1 |
| Brookes, MJ; Gascoyne, LE; Kumar, J; Liddle, EB; Liddle, PF; Morris, PG; Mullinger, KJ; O'Neill, GC; Palaniyappan, L; Robson, SE | 1 |
| Brown, CH; Deutsch, SI; Rosse, RB; Rosse, SM; Schooler, NR; Schwartz, BL | 1 |
| Aaronson, ST; Aitchison, KJ; Buchanan, RW; Dickerson, FB; Koola, MM; Pillai, A; Weinberger, DR | 1 |
| Adams, HA; Blanchard, JJ; Buchanan, RW; Carpenter, WT; Cohen, AS; Gold, J; Kelly, DL; McMahon, RP; Mitchell, KR; Strauss, GP | 1 |
| Boggs, DL; Buchanan, RW; Conley, RR; Dickinson, D; Kelly, DL; McMahon, RP; Weiner, E | 1 |
| Creeden, C; George, TP; Reutenauer, EL; Sacco, KA | 1 |
| Albuquerque, EX; Bruno, JP; Pellicciari, R; Pereira, EF; Schwarcz, R; Wu, HQ | 1 |
| Federley, M; Fjällström, AK; Persson, P; Stenqvist, P; Wadenberg, ML | 1 |
| Attard, A; Jacobsen, P; Patel, SS; Shergill, S | 1 |
| Khan, A; Lindenmayer, JP | 1 |
| Adam, MP; Cubells, JF; Deoreo, EH; Garber, K; Garlow, SJ; Harvey, PD; Martin, CL | 1 |
| Alexander, KS; Bruno, JP; Schwarcz, R; Wu, HQ | 1 |
| Jayaram, MB; Kour, K; Singh, J | 1 |
| Bellack, AS; Billingslea, EN; Deutsch, SI; Mastropaolo, J; Rosse, RB | 1 |
| Arnold, DS; Benham, R; Deutsch, SI; Dickinson, D; Nelson, MW; Rosse, RB | 1 |
| Buchanan, RW; Nelson, MW | 1 |
| Clark, E; Ochoa, EL | 1 |
| Björner, A; Eriksson, L; Norén, U; Sonesson, O | 1 |
| Hicks, PB; Schubert, MH; Young, KA | 1 |
| Robert Brashear, H; Spivey, JM | 1 |
| Kim, YH; Lee, BJ; Lee, JG; Lee, SW | 1 |
| Furukawa, H; Nabeshima, T; Nitta, A; Noda, Y; Wang, D; Zhou, Y | 1 |
| Campbell, C; Caroff, SN; Gallop, R; Lorry, A; Lynch, K; Petro, C; Walker, P | 1 |
| Deutsch, SI; Gaskins, BL; Long, KD; Mastropaolo, J; Rosse, RB; Schooler, NR; Schwartz, BL | 1 |
| Kircher, T; Leucht, S; Thienel, R; Voss, B | 1 |
| Ball, MP; Buchanan, RW; Conley, RR; Dickinson, D; Feldman, S; Gold, JM; McMahon, RP | 1 |
| Culhane, MA; Deckersbach, T; Dyer, MA; Evins, AE; Freudenreich, O; Goff, DC; Murphy, E; Pachas, GN | 1 |
| Allen, TB; McEvoy, JP | 1 |
| Fakturovich, AIa; Golenkov, AV; Lukin, VO; Vovin, RIa | 1 |
5 review(s) available for galantamine and Schizophrenia
| Article | Year |
|---|---|
Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.
Topics: Cognition; Cognitive Dysfunction; Drug Therapy, Combination; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2020 |
Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
Topics: Animals; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Memantine; Nootropic Agents; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Hallucinations; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Acetylcholinesterase inhibitors for schizophrenia.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology | 2012 |
[Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Physostigmine; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
15 trial(s) available for galantamine and Schizophrenia
| Article | Year |
|---|---|
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Cytidine Diphosphate Choline; Galantamine; Humans; Nicotinic Agonists; Nootropic Agents; Pilot Projects; Schizophrenia | 2023 |
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
Topics: Administration, Intranasal; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Oxytocics; Oxytocin; Pessimism; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Kynurenine; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Retrospective Studies; Schizophrenia; Signal Transduction; Young Adult | 2018 |
Changes in electrophysiological markers of cognitive control after administration of galantamine.
Topics: Adult; Beta Rhythm; Brain; Cognition; Double-Blind Method; Electrophysiological Phenomena; Female; Galantamine; Humans; Male; Nootropic Agents; Photic Stimulation; Psychomotor Performance; Schizophrenia; Schizophrenic Psychology; Young Adult | 2018 |
Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Topics: Adult; Aged; alpha7 Nicotinic Acetylcholine Receptor; Cognition Disorders; Cytidine Diphosphate Choline; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Synaptic Transmission; Treatment Outcome | 2013 |
The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.
Topics: Adult; Antipsychotic Agents; Facial Expression; Galantamine; Humans; Interpersonal Relations; Interview, Psychological; Middle Aged; Neuropsychological Tests; Oxytocin; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Social Behavior; Speech Production Measurement; Treatment Outcome; Video Recording; Voice; Young Adult | 2017 |
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Breath Tests; Carbon Monoxide; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Psychiatric Status Rating Scales; Psychotic Disorders; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Self Medication; Smoking Cessation | 2008 |
Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Attention; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Cessation | 2008 |
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Injections, Intramuscular; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia | 2011 |
Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Psychotic Disorders; Risperidone; Schizophrenia | 2006 |
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; Cognition; Cognition Disorders; Color Perception; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Mental Recall; Mental Status Schedule; Middle Aged; Nootropic Agents; Recognition, Psychology; Schizophrenia; Treatment Outcome | 2007 |
Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
Topics: Adult; Antipsychotic Agents; Cholinesterase Inhibitors; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Galantamine; Humans; Male; Middle Aged; Schizophrenia; Treatment Outcome | 2007 |
Galantamine for the treatment of cognitive impairments in people with schizophrenia.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Attention; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Practice, Psychological; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Wechsler Scales | 2008 |
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Attention; Cholinesterase Inhibitors; Cognition Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Galantamine; Humans; Inhibition, Psychological; Male; Memory; Middle Aged; Neuropsychological Tests; Placebos; Regression Analysis; Schizophrenia; Schizophrenic Psychology; Smoking; Treatment Outcome | 2008 |
[Correction of apathetic-abulic manifestations of schizophrenia with cholinotropic drugs].
Topics: Adult; Aged; Benactyzine; Drug Therapy, Combination; Emotions; Female; Galantamine; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Psychology | 1991 |
13 other study(ies) available for galantamine and Schizophrenia
| Article | Year |
|---|---|
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Cholinesterase Inhibitors; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Extracellular Fluid; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Microdialysis; Nicotinic Antagonists; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Schizophrenia | 2010 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Extrapyramidal Tracts; Galantamine; Haloperidol; Male; Mecamylamine; Motor Activity; Nicotinic Antagonists; Rats; Rats, Wistar; Receptors, Muscarinic; Risperidone; Schizophrenia; Scopolamine | 2011 |
Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome.
Topics: Adult; Cholinesterase Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 15; Epilepsy; Female; Galantamine; Humans; Male; Mental Disorders; Pharmacogenetics; Phenotype; Rage; Schizophrenia; Syndrome | 2011 |
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Nicotinic; Schizophrenia | 2012 |
Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Drug Antagonism; Galantamine; Image Processing, Computer-Assisted; Injections, Intraperitoneal; Male; Mice; Neuroprotective Agents; Parasympathomimetics; Schizophrenia | 2003 |
Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient.
Topics: Adult; Affective Symptoms; Cholinesterase Inhibitors; Drug Therapy, Combination; Galantamine; Hospitalization; Humans; Male; Middle Aged; Psychotropic Drugs; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Galantamine-induced QTc prolongation.
Topics: Cholinesterase Inhibitors; Galantamine; Humans; Long QT Syndrome; Male; Middle Aged; Schizophrenia | 2006 |
Galantamine may improve attention and speech in schizophrenia.
Topics: Attention; Benzodiazepines; Cholinesterase Inhibitors; Galantamine; Humans; Male; Middle Aged; Olanzapine; Schizophrenia; Speech | 2006 |
Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Chronic Disease; Cognition Disorders; Drug Therapy, Combination; Galantamine; Humans; Neuropsychological Tests; Pilot Projects; Schizophrenia; Severity of Illness Index | 2006 |
Galantamine and QTc prolongation.
Topics: Alzheimer Disease; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Galantamine; Humans; Long QT Syndrome; Schizophrenia; Sick Sinus Syndrome | 2007 |
Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Galantamine; Interpersonal Relations; Male; Mice; Mice, Inbred ICR; Microdialysis; Nootropic Agents; Phencyclidine; Prefrontal Cortex; Risperidone; Schizophrenia | 2007 |
Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cholinesterase Inhibitors; Cytidine Diphosphate Choline; Disease Models, Animal; Dizocilpine Maleate; Drug Interactions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Male; Mice; Nootropic Agents; Schizophrenia | 2008 |
Galantamine for treatment-resistant schizophrenia.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Drug Therapy, Combination; Galantamine; Humans; Male; Middle Aged; Parasympathomimetics; Risperidone; Schizophrenia | 2002 |